Publications by authors named "Thititat Thanachartwet"
Article Synopsis
- The XANAP study confirmed that rivaroxaban is effective and safe for stroke prevention in patients with non-valvular atrial fibrillation in Asia-Pacific, showing low rates of bleeding and strokes.
- The study involved 2,273 patients over a year, mainly older adults with various co-morbidities, and primarily used rivaroxaban 20 mg or 15 mg doses.
- Results indicated a persistence rate of 66.2% for patients continuing treatment, aligning with previous studies like ROCKET AF and XANTUS.
